Endocrinology Market
GLP-1 revolution and next-generation obesity therapies reshaping the metabolic market
Market Overview
The endocrinology market is experiencing unprecedented growth driven by the GLP-1 receptor agonist revolution in diabetes and obesity. With semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) achieving blockbuster status, the metabolic market is being completely transformed. Next-generation therapies including triple agonists (GLP-1/GIP/Glucagon), oral GLP-1s, and muscle-preserving obesity therapies represent a $100B+ opportunity through 2030.
Market Size Forecast (2024–2030)
Projected market value in USD billions
Market Segments
Share by therapeutic segment
Regional Market Analysis
Market share and growth by region
Key Drivers
- ▸GLP-1 receptor agonists transforming diabetes and obesity treatment paradigms
- ▸Obesity recognized as a chronic disease driving massive market expansion
- ▸Tirzepatide (dual GIP/GLP-1) demonstrating unprecedented weight loss efficacy
- ▸Next-generation triple agonists (retatrutide, CagriSema) in late-stage development
- ▸Oral GLP-1 formulations (oral semaglutide, orforglipron) improving accessibility
- ▸Expanding indications: cardiovascular, renal, MASH, sleep apnea, addiction
Challenges
- ▸Manufacturing supply constraints limiting GLP-1 availability
- ▸Payer coverage variability for obesity indications
- ▸Compounding pharmacy competition during shortages
- ▸Reimbursement challenges for chronic obesity treatment
- ▸Long-term safety and tolerability concerns with chronic GLP-1 use
Opportunities
- ▸Obesity market projected to reach $50B+ by 2030
- ▸Triple agonist (retatrutide) demonstrating 24%+ weight loss
- ▸Oral GLP-1 therapies representing $10B+ opportunity for improved convenience
- ▸MASH (NASH) market emerging with GLP-1 and FXR agonist approvals
- ▸Muscle-preserving obesity therapies (bimagrumab, Trevogrumab) as next frontier
- ▸Cardiovascular and renal outcome benefits expanding GLP-1 patient pool
Key Pipeline Drugs
Late-stage and recently approved therapies from Top 20 pharma
| Drug | Company | Phase |
|---|---|---|
Retatrutide (LY3437943) Obesity, type 2 diabetes | Eli Lilly | Phase 3 |
CagriSema (cagrilintide + semaglutide) Obesity, type 2 diabetes | Novo Nordisk | Phase 3 |
Orforglipron (LY3502970) Obesity, type 2 diabetes | Eli Lilly | Phase 3 |
Danuglipron Type 2 diabetes, obesity | Pfizer | Phase 2/3 |
Survodutide (BI 456906) MASH, obesity | Boehringer Ingelheim / Zealand | Phase 3 |
Resmetirom (Rezdiffra) MASH/NASH | Madrigal Pharmaceuticals | Approved |
Bimagrumab Obesity with muscle preservation | Eli Lilly (Versanis) | Phase 2 |
Maridebart cafraglutide (MARITIDE) Obesity, monthly dosing | Amgen | Phase 2 |
Marketed Drugs — Current Landscape
Blockbuster and key marketed therapies shaping the competitive landscape
| Drug | Company | Annual Sales |
|---|---|---|
Ozempic (semaglutide) Diabetes market leader | Novo Nordisk | $14B+ |
Wegovy (semaglutide) Obesity market leader | Novo Nordisk | $5B+ |
Mounjaro (tirzepatide) Fast-growing diabetes therapy | Eli Lilly | $5B+ |
Zepbound (tirzepatide) Obesity launch accelerating | Eli Lilly | $2B+ |
Trulicity (dulaglutide) Mature GLP-1, losing share | Eli Lilly | $7B+ (declining) |
Rybelsus (oral semaglutide) Only approved oral GLP-1 | Novo Nordisk | $2B+ |
Lantus (insulin glargine) Biosimilar erosion | Sanofi | $3B+ (declining) |
Tresiba (insulin degludec) Premium basal insulin | Novo Nordisk | $1.5B+ |
Competitive Landscape
Tiered analysis of companies shaping the endocrinology market
Tier 1 — Metabolic Leaders
Dominant GLP-1 and insulin franchises driving the metabolic market transformation
Tier 2 — Metabolic Challengers
Pursuing oral GLP-1, novel mechanisms, and next-generation obesity therapies
Tier 3 — Emerging Innovators
Novel approaches in MASH, muscle preservation, and oral peptide therapeutics
Our Research Methodology
KOL Network
40+ interviews with endocrinologists, diabetologists, obesity medicine specialists, and payers across US, EU5, and APAC to validate treatment paradigms.
Obesity Market Modeling
Epidemiology-based obesity market sizing by BMI category, treatment-eligible population, and payer coverage scenarios across key markets.
Pipeline Analytics
Tracking of 400+ endocrinology pipeline assets with focus on GLP-1 next-gen, oral formulations, MASH, and muscle-preserving therapies.
Payer & Access Analysis
Coverage analysis for obesity therapies across US commercial, Medicare Part D, and EU payer systems with pricing strategy recommendations.
Supply Chain & Manufacturing
Analysis of GLP-1 manufacturing capacity, peptide synthesis CDMO landscape, and supply-demand projections through 2030.
How We Help Clients Win in Endocrinology
Our consulting engagements combine deep therapeutic expertise with proprietary intelligence to identify where the opportunity lies — and how to capture it.
Obesity Market Entry Strategy
Develop market entry strategies for next-generation obesity therapies including positioning, pricing, and payer access
GLP-1 Lifecycle Management
Extend GLP-1 franchise with indication expansion, formulation innovation, and combination strategies
MASH Market Strategy
Navigate the emerging MASH market with first-mover strategies and KOL engagement
Oral GLP-1 Launch Strategy
Optimize launch of oral GLP-1 therapies with convenience positioning, pricing strategy, and market access
Frequently Asked Questions
What is driving the explosive growth in the endocrinology market?
The GLP-1 receptor agonist revolution is the primary driver, with semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) achieving blockbuster status. Next-generation triple agonists, oral GLP-1s, and expanding indications in obesity, MASH, and cardiovascular disease are creating a $100B+ opportunity.
How large is the obesity pharmaceutical market?
The obesity pharmaceutical market is projected to reach $50B+ by 2030, driven by GLP-1 therapies, next-generation dual and triple agonists, and expanding payer coverage. This represents one of the largest growth opportunities in pharmaceuticals.
How can Medifirm help with endocrinology and obesity strategy?
We provide comprehensive endocrinology market intelligence including obesity market modeling, GLP-1 competitive analysis, pipeline tracking, payer access strategy, supply chain analysis, and launch strategy for next-generation metabolic therapies.